LGI1 and encephalitis: In a cohort study that included 27 cases of anti-NMDAR encephalitis and 3 cases of anti-leucine-rich glioma inactivated-1 (LGI1) encephalitis, mRS scores improved more in the rituximab treated group, both in the group that responded to first-line therapy (88% vs 83.3%) and in the group that did not respond to first-line therapy (60% vs 22.2%) (15).